Lyell Immunopharma Inc.

0.48
-0.03 (-5.42%)
At close: Apr 03, 2025, 12:57 PM

Lyell Immunopharma Statistics

Share Statistics

Lyell Immunopharma has 295.23M shares outstanding. The number of shares has increased by 15.8% in one year.

Shares Outstanding 295.23M
Shares Change (YoY) 15.8%
Shares Change (QoQ) 1.05%
Owned by Institutions (%) 58.63%
Shares Floating 124.87M
Failed to Deliver (FTD) Shares 695
FTD / Avg. Volume 0.07%

Short Selling Information

The latest short interest is 12.4M, so 4.24% of the outstanding shares have been sold short.

Short Interest 12.4M
Short % of Shares Out 4.24%
Short % of Float 8.22%
Short Ratio (days to cover) 10.75

Valuation Ratios

The PE ratio is -0.49 and the forward PE ratio is -1.35. Lyell Immunopharma's PEG ratio is -0.01.

PE Ratio -0.49
Forward PE -1.35
PS Ratio 2743.4
Forward PS 2735.3
PB Ratio 0.44
P/FCF Ratio -1.03
PEG Ratio -0.01
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Lyell Immunopharma.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 7.06, with a Debt / Equity ratio of 0.13.

Current Ratio 7.06
Quick Ratio 7.06
Debt / Equity 0.13
Debt / EBITDA -15.41
Debt / FCF -0.31
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $203.33
Profits Per Employee $-1.14M
Employee Count 300
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax 0
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by -75.24% in the last 52 weeks. The beta is -0.42, so Lyell Immunopharma's price volatility has been lower than the market average.

Beta -0.42
52-Week Price Change -75.24%
50-Day Moving Average 0.61
200-Day Moving Average 1.07
Relative Strength Index (RSI) 41.63
Average Volume (20 Days) 1.03M

Income Statement

In the last 12 months, Lyell Immunopharma had revenue of 61K and earned -342.99M in profits. Earnings per share was -1.31.

Revenue 61K
Gross Profit 61K
Operating Income -3.31M
Net Income -342.99M
EBITDA -3.31M
EBIT n/a
Earnings Per Share (EPS) -1.31
Full Income Statement

Balance Sheet

The company has 105.6M in cash and 50.99M in debt, giving a net cash position of 54.6M.

Cash & Cash Equivalents 105.6M
Total Debt 50.99M
Net Cash 54.6M
Retained Earnings -1.35B
Total Assets 490.86M
Working Capital 325.81M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -162.39M and capital expenditures -464K, giving a free cash flow of -162.86M.

Operating Cash Flow -162.39M
Capital Expenditures -464K
Free Cash Flow -162.86M
FCF Per Share -0.62
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -5424.59% and -562285.25%.

Gross Margin 100%
Operating Margin -5424.59%
Pretax Margin -562285.25%
Profit Margin -562285.25%
EBITDA Margin -5424.59%
EBIT Margin -5424.59%
FCF Margin -266980.33%

Dividends & Yields

LYEL does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for LYEL is $1, which is 96.1% higher than the current price. The consensus rating is "Hold".

Price Target $1
Price Target Difference 96.1%
Analyst Consensus Hold
Analyst Count 2
Stock Forecasts

Scores

Altman Z-Score -3.73
Piotroski F-Score 2